Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug HEC89736 tested in blood cancer patients – but trial stopped early

NCT ID NCT04865458

Disease control Sponsor: Sunshine Lake Pharma Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called HEC89736 in people with B-cell blood cancers that had returned or stopped responding to treatment. The study aimed to check the drug's safety and how the body processes it. Only 5 people took part before the trial was terminated, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HEC89736 (an experimental oral drug)
What this could lead to
If it works, this could point toward a new treatment option for people with certain blood cancers that have come back or not responded to other therapies.
What could go wrong
This was a very early, small trial (only 5 people) that was terminated early, so we have very little data. The drug may not be effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

5 people

The number who actually took part.

Started

Apr 2021

Finished

Sep 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age is over 18 years old * Histologically or cytologically diagnosed patients with recurrent or refractory B-cell malignancies * ECOG performance status (PS) 0 \~ 1 * Expected survival of \> or = 3 months Exclusion Criteria: * The use of PI3Ks as the target of anti-tumor drugs progress (due to intolerance group) * Received any other anti-cancer treatment within 4 weeks * Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors that affect drug use and absorption * Allergy, or known to have a history of allergy to the drug components

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed or refractory B-cell hematologic malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Recurrence refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed or refractory B-cell hematologic malignancies

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China